<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507348</url>
  </required_header>
  <id_info>
    <org_study_id>38RC17.247</org_study_id>
    <nct_id>NCT03507348</nct_id>
  </id_info>
  <brief_title>Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates</brief_title>
  <official_title>Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kidney transplantation is the best renal-replacement in the setting of end-stage renal
      disease. However, some transplant candidates have developed anti-HLA alloantibodies (human
      leukocyte antigen). When they are numerous and when their strength assessed by mean
      fluorescence intensity (MFI) is high it is very complicated to find-out a suitable kidney
      allograft against which the recipient has a negative cross-match. In such a case the only
      hope for the patient is desensitization therapy, whereby the treatment will decrease anti-HLA
      alloantibodies below a threshold, i.e. MFI &lt; 3,000, enabling kidney transplantation without
      risking antibody-mediated rejection. Desensitization relies on i) apheresis technics in order
      to withdraw circulating anti-HLA antibodies, and ii) immunosuppression, i.e. rituximab or
      tocilizumab, targeting B-lymphocytes, and tacrolimus/mycophenolic acid/steroids targeting
      T-cells. The type of apheresis is guided by the pre-desensitization MFI of anti-HLA
      alloantibodies, e.g. double filtration plasmapheresis or semispecific immunoadsorption.
      Likely the choice between rituximab and tocilizumab depends also on predesensitization
      anti-HLA antibody MFIs. At the end of the desensitization process, the patient will be able
      to get a kidney transplant either from a live-donor or from a deceased donor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the results of the strategy of desensitization in patients who will access to kidney transplantation from deceased or living donors.</measure>
    <time_frame>at day 1 start of desensitization, at day 0 of Graft</time_frame>
    <description>Decrease of MFI for highest donor-specific alloantibody (DSA) between start and end of desensitization for every patient in each category</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Desensitization efficacy with regards to DSA decrease and kidney transplantation</measure>
    <time_frame>Day-198, at day-30 Graft, at day-15, at day0 of Graft,</time_frame>
    <description>MFI for highest DSAs for each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impairment of DSA synthesis</measure>
    <time_frame>Day-198, at day-30 Graft, at day-15, at day0 of Graft,</time_frame>
    <description>Decrease in peripheral plasma cells and plasmablasts of &gt;50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impairment of immune response</measure>
    <time_frame>Day-198, at day-30 Graft, at day-15, at day0 of Graft,</time_frame>
    <description>Decrease in complement factors of &gt;25%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment desensitization protocols, emergent adverse events (safety and Tolerability)</measure>
    <time_frame>Day-198, at day-30 Graft, at day-15</time_frame>
    <description>Emergent adverse events to the desensitization therapy will be carefully monitored during the treatment period and within the following three months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>End-stage Renal Disease</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Hla-incompatible Kidney Transplant Candidates</condition>
  <arm_group>
    <arm_group_label>Desensitization with Tocilizumab and rituximab (MFI &gt;15000)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Desensitization with Rituximab only (MFI&lt;15000)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>visits of tocilizumab injection (every 4 weeks, up to 5 visits)</intervention_name>
    <description>every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).</description>
    <arm_group_label>Desensitization with Tocilizumab and rituximab (MFI &gt;15000)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab 375 mg/m2 at Day-30</intervention_name>
    <description>Rituximab 375 mg/m2 at Day-30</description>
    <arm_group_label>Desensitization with Tocilizumab and rituximab (MFI &gt;15000)</arm_group_label>
    <arm_group_label>Desensitization with Rituximab only (MFI&lt;15000)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab 375 mg/m2 at Day-15 (only for donors living)</intervention_name>
    <description>Rituximab 375 mg/m2 at Day-15</description>
    <arm_group_label>Desensitization with Tocilizumab and rituximab (MFI &gt;15000)</arm_group_label>
    <arm_group_label>Desensitization with Rituximab only (MFI&lt;15000)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transplant Day-0</intervention_name>
    <description>TRANSPLANTATION</description>
    <arm_group_label>Desensitization with Tocilizumab and rituximab (MFI &gt;15000)</arm_group_label>
    <arm_group_label>Desensitization with Rituximab only (MFI&lt;15000)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on the kidney transplant list, waiting for a first or repeat transplant

          -  Presence of anti HLA antibodies either class I and/or II

          -  Sensitized against a potential living donor or have been on the waiting list for at
             least 3 years and having no potential live-donor

          -  Patients eligible for desensitization will receive either rituximab alone, or
             rituximab plus apheresis, or tocilizumab before rituximab

          -  Normal recent (&lt;6 months) cardiac workup

          -  Vaccinated against pneumococcus and meningococcus B and C

          -  Willingness of the patient to undergo the desensitization process and Express consent
             of the patient

          -  for women of childbearing age, effective contraception or abstinence

          -  Affiliated to a social security scheme or of such a scheme

        Exclusion Criteria:

          -  Active underlying infections or neoplasia

          -  Pregnant women, parturient or breastfeeding

          -  Subject in exclusion period of another study

          -  Subject under administrative or judicial control

          -  Subject who cannot be contacted in an emergency

          -  Rituximab contra indication: hypersensitivity (to active substance or murine protein),
             active and severe infections, patients in a severely immunocompromised state, severe
             heart failure or severe, uncontrolled cardiac disease.

          -  Tocilizumab contra indication: hypersensitivity, active and severe infections.
             Apheresis contra indication: active and severe infection, untreated or instable
             coagulation disorders, unstable coronary disease, recent stroke, hemodynamic
             instability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AIDA MANDOZO, ARC prom</last_name>
    <phone>04 76 76 68 16</phone>
    <phone_ext>033</phone_ext>
    <email>amandozo@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Farida Imerzoukene, ARC</last_name>
    <phone>0476767022</phone>
    <phone_ext>033</phone_ext>
    <email>fimerzoukene@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grenoble Alpes University Hospital</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel ROSTAING, PH MD</last_name>
      <phone>0033476767022</phone>
      <email>Lrostaing@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>LIONEL ROSTAING, PH MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>PAOLO MALVEZZI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Orandi BJ, Montgomery RA, Segev DL. Kidney Transplants from HLA-Incompatible Live Donors and Survival. N Engl J Med. 2016 Jul 21;375(3):288-9. doi: 10.1056/NEJMc1604523.</citation>
    <PMID>27468073</PMID>
  </results_reference>
  <results_reference>
    <citation>Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011 Jul 28;365(4):318-26. doi: 10.1056/NEJMoa1012376.</citation>
    <PMID>21793744</PMID>
  </results_reference>
  <results_reference>
    <citation>Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, Ge S, Toyoda M, Kahwaji J, Peng A, Villicana R, Jordan SC. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014 Aug 15;98(3):312-9. doi: 10.1097/TP.0000000000000064.</citation>
    <PMID>24770617</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahwaji J, Jordan SC, Najjar R, Wongsaroj P, Choi J, Peng A, Villicana R, Vo A. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Int. 2016 Dec;29(12):1276-1285. doi: 10.1111/tri.12832. Epub 2016 Oct 24.</citation>
    <PMID>27529314</PMID>
  </results_reference>
  <results_reference>
    <citation>Klein K, Süsal C, Schäfer SM, Becker LE, Beimler J, Schwenger V, Zeier M, Schemmer P, Macher-Goeppinger S, Scherer S, Opelz G, Morath C. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atheroscler Suppl. 2013 Jan;14(1):199-202. doi: 10.1016/j.atherosclerosissup.2012.10.030.</citation>
    <PMID>23357165</PMID>
  </results_reference>
  <results_reference>
    <citation>Rostaing L, Maggioni S, Hecht C, Hermelin M, Faudel E, Kamar N, Sallusto F, Doumerc N, Allal A. Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates. Exp Clin Transplant. 2015 Apr;13 Suppl 1:165-9.</citation>
    <PMID>25894148</PMID>
  </results_reference>
  <results_reference>
    <citation>Kauke T, Klimaschewski S, Schoenermarck U, Fischereder M, Dick A, Guba M, Stangl M, Werner J, Meiser B, Habicht A. Outcome after Desensitization in HLA or ABO-Incompatible Kidney Transplant Recipients: A Single Center Experience. PLoS One. 2016 Jan 5;11(1):e0146075. doi: 10.1371/journal.pone.0146075. eCollection 2016.</citation>
    <PMID>26730981</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-HLA alloantibodies</keyword>
  <keyword>Desensitization therapy</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

